Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2000 1
2001 1
2003 2
2014 1
2017 1
2018 2
2019 5
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L. Stock S, et al. Among authors: gern u. Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28. Int J Cancer. 2019. PMID: 30737788 Free article.
Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L. Gong W, et al. Among authors: gern u. Cancer Immunol Immunother. 2019 Jul;68(7):1195-1209. doi: 10.1007/s00262-019-02354-4. Epub 2019 Jun 8. Cancer Immunol Immunother. 2019. PMID: 31177329
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, Hückelhoven-Krauss A, Kunz A, Gern U, Michels B, Hinkelbein M, Mechler S, Richter P, Müller-Tidow C, Schmitt M, Schmitt A. Wang L, et al. Among authors: gern u. Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23. Cytotherapy. 2019. PMID: 30910382
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, Hückelhoven-Krauss A, Kulozik A, Ho AD, Müller-Tidow C, Dreger P, Schmitt M. Schubert ML, et al. Among authors: gern u. BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644. BMJ Open. 2019. PMID: 31110096 Free PMC article. Clinical Trial.
Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients.
Kunz A, Gern U, Schmitt A, Neuber B, Wang L, Hückelhoven-Krauss A, Michels B, Hofmann S, Müller-Tidow C, Dreger P, Schmitt M, Schubert ML. Kunz A, et al. Among authors: gern u. Mol Ther Methods Clin Dev. 2020 Feb 20;17:448-454. doi: 10.1016/j.omtm.2020.02.003. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32201711 Free PMC article.
15 results